Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line MTAP-deleted metastatic non-small cell lung cancer
MOH_2026-01-08_015593Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MRTX1719 in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Bristol Myers Squibb. Started Dec 2025; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2026-01-08_015593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-08_015593.